Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

doi:10.1158/1078-0432.CCR-05-0899

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2005

Concin Nicole, Hofstetter Gerda, Berger Astrid, Gehmacher Adriana, Reimer Daniel, Watrowski Rafal, Tong Dan, Schuster Eva, Hefler Lukas, Heim Kurt, Mueller-Holzner Elisabeth, Marth Christian, Moll Ute M, Zeimet Alain G, Zeillinger Robert

Abstract excerpt

PURPOSE: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72. EXPERIMENTAL DESIGN: A detailed analysis of p53 and p73 in a series of 122 ovarian cancers was done. We used a functional yeast-based assay to determine the p53 mutational...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Mucinous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Endometrioid

Share to Cystadenocarcinoma, Serous

Share to Genes, Tumor Suppressor

Share to Protein Isoforms

Share to Survival Rate

Share to Tumor Protein p73

Share to Tumor Suppressor Proteins

Source

Open in PubMed

Identifiers

PMID: 16322298
DOI: 10.1158/1078-0432.CCR-05-0899

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.PMID 16322298Read ↗

Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in VivoSemantic proximity Read ↗

The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting.Semantic proximity Read ↗

DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.Semantic proximity Read ↗

Targeting p73 in cancer.Semantic proximity Read ↗

Chemosensitivity linked to p73 function.Semantic proximity Read ↗

Role of p53 family members p73 and p63 in human hematological malignanciesSemantic proximity Read ↗

Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished AffairSemantic proximity Read ↗

In good times and bad: p73 in cancerSemantic proximity Read ↗

p73, a sophisticated p53 family member in the cancer world.Semantic proximity Read ↗

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.Semantic proximity Read ↗

p73 as a Pharmaceutical Target for Cancer TherapySemantic proximity Read ↗

Clinical implications of the deregulated TP73 isoforms expression in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.